Synthetic Biology – News and Features

Intrexon Corporation announced that it has closed a Series F preferred investment round of $150 million, bringing the company’s total capital raised to $509 million.

Scientists have developed a new type of nanoparticle with potential applications in chemistry, biology and medicine.

Combined expertise to create new generation of bacteriophage-based therapeutics for antibiotic resistant infections.

Twelve years after a breakthrough discovery in his UC Berkeley laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true.

Eight synthetic biology (synbio) companies have joined the BioIndustry Association (BIA) to form a new group working on this emerging area of bioscience.

Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals.

Cutting-edge synthetic biology companies received a boost today with a £5.3 million government cash injection.

Joint BioEnergy Institute researchers engineer plant cell walls to boost sugar yields for biofuels.

New technologies to produce vaccines more safely, quickly and economically than traditional approaches are featured at the New Cells, New Vaccines VII: From Protein to Product international scientific conference.

Grant will allow Prokarium to complete preclinical work on Typhetec®.